Matthew Meyer

Dr. Meyer is a protein biochemist with broad expertise in the field of proteomics including mass spectrometry-based protein biomarker discovery, identification of post-translational modifications, and targeted, quantitative LC-MS assay development on multiple platforms.During his postdoctoral training at Washington University, Dr. Meyer focused on translational research establishing mass spectrometry workflows for quantitative, multiplexed assays as part of the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC). While at Washington University, he successfully developed novel strategies for the enrichment and quantification of over 200 kinases in the human breast cancer kinome. He received his BS in Biochemistry from the University of Missouri-Columbia and his PhD in Biochemistry from Iowa State University.At C2N Diagnostics he helped develop the components of the PrecivityADTM test and validated the test under CLIA standards. Dr. Meyer currently leads the R&D lab operations where they are focused on the development and automation of C2N’s novel LC-MS based, biomarker assays.